Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

ClinicalTrials.gov ID: NCT03124108

Public ClinicalTrials.gov record NCT03124108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg After 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid

Study identification

NCT ID
NCT03124108
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genfit
Industry
Enrollment
45 participants

Conditions and interventions

Interventions

  • Elafibranor 80 mg Drug
  • Elafibranor 120 mg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 4, 2017
Primary completion
Oct 30, 2018
Completion
Oct 30, 2018
Last update posted
Sep 23, 2019

2017 – 2018

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Mayo Clinic in Arizona Phoenix Arizona 85054
Schiff Center for Liver Diseases Miami Florida 33136
Cleveland Clinic Florida Weston Florida 33331
Piedmont Research Institute Atlanta Georgia 30309
Massachusetts General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Northwell Health Institution Manhasset New York 11030
Asheville Gastroenterology Associates Asheville North Carolina 28801
UT Southwestern Medical Center Dallas Texas 75390
Baylor College of Medicine Houston Texas 77030
University of Virginia Charlottesville Virginia 22903
Virginia Commonwealth University Richmond Virginia 23298
Swedish Medical Center Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03124108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03124108 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →